Arrowhead Pharmaceuticals
ARWR · Biotechnology
$58.02
0.6%Krystal Biotech
KRYS · Biotechnology
$311.50
2.7%The short version
- Arrowhead Pharmaceuticals is the larger business, with $829M of revenue in fiscal 2025 against $389M for Krystal Biotech, about 2.1 times as much.
- Arrowhead Pharmaceuticals grew revenue faster (23,258.2%, against 33.9%).
- Krystal Biotech kept more of each dollar of sales as operating profit (41.5% operating margin, against 11.9% operating margin).
- Krystal Biotech turned more of its sales into free cash flow (48.6% FCF margin, against 18.9% FCF margin).
| Latest fiscal year | ARWR · FY25 | KRYS · FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.3B | $9.6B |
| Revenue | $829M | $389M |
| Free cash flow | $157M | $189M |
| Net income | −$1.6M | $205M |
| Growth | ||
| Revenue growth | 23,258.2% | 33.9% |
| 5-year growth | 56.6% | — |
| Share count change | 11.7% | 0.7% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | 11.9% | 41.5% |
| Net margin | −0.2% | 52.6% |
| FCF margin | 18.9% | 48.6% |
| Return on capital | — | 43.6% |
| Return on equity | −0.5% | 18.9% |
| Balance sheet | ||
| Net debt | −$665M | −$828M |
| Net debt / EBITDA | −5.5x | −5.0x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | — | 39.0x |
| Piotroski F-score | 5 | 5 |
FY16
ARWR $0.2M
KRYS —
FY17
ARWR $31.4M
KRYS —
FY18
ARWR $16.1M
KRYS —
FY19
ARWR $169M
KRYS —
FY20
ARWR $88.0M
KRYS —
FY21
ARWR $138M
KRYS $0.0M
FY22
ARWR $243M
KRYS $0.0M
FY23
ARWR $241M
KRYS $50.7M
FY24
ARWR $3.6M
KRYS $291M
FY25
ARWR $829M
KRYS $389M
ARWR
KRYS
FY16
ARWR −51,627.1%
KRYS —
FY17
ARWR −117.8%
KRYS —
FY18
ARWR −346.5%
KRYS —
FY19
ARWR 36.3%
KRYS —
FY20
ARWR −105.9%
KRYS —
FY21
ARWR −107.8%
KRYS —
FY22
ARWR −73.4%
KRYS —
FY23
ARWR −85.2%
KRYS −216.2%
FY24
ARWR −16,927.1%
KRYS 22.6%
FY25
ARWR 11.9%
KRYS 41.5%
ARWR
KRYS
FY16
ARWR −$68.3M
KRYS −$1.3M
FY17
ARWR −$31.9M
KRYS −$4.1M
FY18
ARWR −$48.6M
KRYS −$11.7M
FY19
ARWR $161M
KRYS −$25.1M
FY20
ARWR −$108M
KRYS −$40.9M
FY21
ARWR $148M
KRYS −$116M
FY22
ARWR −$189M
KRYS −$154M
FY23
ARWR −$331M
KRYS −$101M
FY24
ARWR −$604M
KRYS $119M
FY25
ARWR $157M
KRYS $189M
ARWR
KRYS
FY16
ARWR —
KRYS —
FY17
ARWR −82.4%
KRYS —
FY18
ARWR −70.2%
KRYS —
FY19
ARWR 136.1%
KRYS —
FY20
ARWR −57.6%
KRYS —
FY21
ARWR −71.2%
KRYS −61.2%
FY22
ARWR −69.1%
KRYS −76.9%
FY23
ARWR −167.1%
KRYS −47.7%
FY24
ARWR —
KRYS 20.7%
FY25
ARWR —
KRYS 43.6%
ARWR
KRYS
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.